Synovial Sarcoma Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Epidemiology, Therapies, Companies by DelveInsight

(Albany, USA) The Synovial Sarcoma market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Takara Bio Inc., Foghorn Therapeutics Inc., Onco Therapy Science Inc., C4 Therapeutics Inc., Adaptimmune, Advenchen Laboratories LLC, Epizyme Inc., GlaxoSmithKline, Ipsen, Bayer, Eli Lilly and Company, Sumitomo Pharma Oncology Inc.

[Nevada, United States] - DelveInsight's "Synovial Sarcoma Market Insights, Epidemiology, and Market Forecast 2034." report offers a detailed examination of Synovial Sarcoma, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Synovial Sarcoma Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/report-store/synovial-sarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Findings from the Synovial Sarcoma Market Report:
The Synovial Sarcoma market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2020-2034).
In July, 2024: Epizyme, Inc.announced that their study will include participants with various types of cancer known as soft-tissue sarcomas. Tissues that can be affected by soft tissue sarcomas include fat, muscle, blood vessels, deep skin tissues, tendons and ligaments.
In April, 2024: Adaptimmune announced that a pediatric basket study to investigate the safety and efficacy of afamitresgene autoleucel in HLA-A*02 eligible and MAGE-A4 positive subjects aged 2-21 years of age with advanced cancers
In July, 2024: Adaptimmune announced that their trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumors.
Synovial sarcoma is a rare cancer, with an incidence rate of approximately 1.5-2.75 cases per million people per year globally. In the United States, this equates to around 900-1,000 new cases annually.
In the 7MM, the total incident cases of synovial sarcoma in 2023 were ~1,600 out of which the highest cases of this disease were seen in the United States
The incidence of synovial sarcoma has been estimated to be very low and rare, accounting for only 5-10% of all soft tissue sarcoma. This means a small patient target for new entrants.
Key Synovial Sarcoma Companies are as follows: Takara Bio Inc., Foghorn Therapeutics Inc., Onco Therapy Science Inc., C4 Therapeutics Inc., Adaptimmune, Advenchen Laboratories LLC, Epizyme Inc., GlaxoSmithKline, Ipsen, Bayer, Eli Lilly and Company, Sumitomo Pharma Oncology Inc.
Key Synovial Sarcoma Therapies are as follow: Cyclophosphamide, AL3818, Dacarbazine, Sorafenib and Dacarbazine, IMC-A12, soblidotin, Doxorubicin, APX005M, pazopanib, Tazemetostat
Launching multiple stage Synovial Sarcoma pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Synovial Sarcoma market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/sample-request/synovial-sarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Synovial Sarcoma Overview:
Synovial sarcoma is cancer that can originate from different types of soft tissue, such as muscle or ligaments. It is often found inthe arm, leg, or foot and near joints such as the wrist or ankle. It can also form in soft tissues in the lung or abdomen. Synovialsarcoma may also be called malignant synovioma. It accounts for 5-10% of soft-tissue tumors. For every one million people, oneto two are diagnosed with synovial sarcoma per year in the US.

Synovial Sarcoma Epidemiology Segmentation:
The Synovial Sarcoma market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
Incident Cases of Synovial Sarcoma
Location-specific Cases of Synovial Sarcoma
Antigens-specific (MAGE-A4, NY-ESO-1, PRAME, and others) Cases of Synovial Sarcoma
Age-specific Cases of Synovial Sarcoma
Stage-specific Cases of Synovial Sarcoma
Gender-specific cases of Synovial Sarcoma

For more information about Synovial Sarcoma companies working in the treatment market, visit https://www.delveinsight.com/sample-request/synovial-sarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Synovial Sarcoma Market Insights
Synovial sarcoma is a rare sarcoma driven by a translocation between SS18 and SSX 1, 2, or 4. The hybrid transcriptionfactor SS18: SSX alters SWItch/Sucrose Non-Fermentable (SWI/SNF) chromatin remodeling and global methylation patternsthat may allow for future therapeutic opportunities.

Synovial Sarcoma Drugs Uptake
Trabectedin (VOTRIENT), an antitumor agent is approved in Europe for the treatment of adult patients withadvanced soft tissue sarcoma after failure of anthracyclines (doxorubicin) and ifosfamide, or those who are unfit toreceive these agents whereas in US, it has been approved for specific types of STS but its utility as a therapeutictreatment for synovial sarcoma is uncertain
Pazopanib (ONDELIS) is an oral multitarget tyrosine kinase inhibitor (TKI) with a clinical antitumor effect that is thoughtto be exerted through its selective inhibition of vascular endothelial growth factor receptor (VEGFR)-mediatedangiogenesis, as well as its direct blockade of growth-promoting receptor tyrosine kinases (RTKs)
As per latest treatment paradigms chemotherapy regimen is administered for a fixed number of cycles followed by awatchful waiting approach to assess the optimum response. Doxorubicin and Ifosfamideconstitute the first lineapproach thereby helping generate a large chunk of the revenue

Dive into our comprehensive market research report to discover in-depth insights, emerging trends, and strategic opportunities @ https://www.delveinsight.com/sample-request/synovial-sarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Synovial Sarcoma Therapies and Key Companies:
Cyclophosphamide: Takara Bio Inc.
AL3818, Dacarbazine: Advenchen Laboratories, LLC
Sorafenib and Dacarbazine: Memorial Sloan Kettering Cancer Center
IMC-A12: Eli Lilly and Company
soblidotin: Daiichi Sankyo
Doxorubicin, APX005M: Alexander Z. Wei, MD
pazopanib: GlaxoSmithKline
Tazemetostat: Epizyme, Inc.

Synovial Sarcoma Epidemiology:
The epidemiology section provides insights into historical, current, and forecasted trends in the seven major countries (7MM) from 2020 to 2034. It explores various studies and opinions to recognize the causes of current and forecasted trends. The segmentation includes total prevalence, severity-based prevalence, gender-specific prevalence, and diagnosed cases of episodic and chronic Synovial Sarcoma.

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/synovial-sarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Synovial Sarcoma Market Drivers:
Advancements in Targeted Therapies
Increased Focus on Biomarkers and Personalized Medicine
Orphan Drug Designation and Regulatory Support
Ongoing Clinical Trials and Emerging Treatments

Synovial Sarcoma Market Barriers:
Rarity of the Disease
High Cost of Emerging Therapies
Limited Therapeutic Options for Advanced Disease
Complexity of Disease and Heterogeneity

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/synovial-sarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Synovial Sarcoma Market Report:
Study Period: 2020-2034
Coverage: 7MM (The United States, EU5, and Japan)
Key Synovial Sarcoma Companies: Takara Bio Inc., Foghorn Therapeutics Inc., Onco Therapy Science Inc., C4 Therapeutics Inc., Adaptimmune, Advenchen Laboratories LLC, Epizyme Inc., GlaxoSmithKline, Ipsen, Bayer, Eli Lilly and Company, Sumitomo Pharma Oncology Inc.
Key Synovial Sarcoma Therapies: Cyclophosphamide, AL3818, Dacarbazine, Sorafenib and Dacarbazine, IMC-A12, soblidotin, Doxorubicin, APX005M, pazopanib, Tazemetostat
Synovial Sarcoma Therapeutic Assessment: Current marketed and emerging therapies
Synovial Sarcoma Market Dynamics: Synovial Sarcoma Market drivers and Synovial Sarcoma barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Synovial Sarcoma Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Synovial Sarcoma market outlook, drug uptake, treatment scenario, and epidemiology trends, https://www.delveinsight.com/sample-request/synovial-sarcoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Content:

1 Key Insights
2 Report Introduction
3 Synovial Sarcoma Market Overview at a Glance
4 Methodology of Synovial Sarcoma Epidemiology and Market
5 Executive Summary of Synovial Sarcoma
6 Disease Background and Overview
7 Epidemiology and Patient Population
8 Key Events
9 Patient Journey
10 Marketed Drugs
11 Emerging Products
12 Synovial Sarcoma: Market Analysis
13 Unmet Needs
14 SWOT Analysis
15 KOL Views
16 Market Access and Reimbursement
16.4 Market Access and Reimbursement of synovial sarcoma
17 Appendix
18 DelveInsight Capabilities
19 Disclaimer
20 About DelveInsight

Trending Reports:
• Precocious Puberty Market: https://www.delveinsight.com/report-store/precocious-puberty-market
• Surgical Site Infections Market: https://www.delveinsight.com/report-store/surgical-site-infections-ssi-market
• Achromatopsia Market: https://www.delveinsight.com/report-store/achromatopsia-market
• Acute On Liver Failure Market: https://www.delveinsight.com/infographics/acute-on-chronic-liver-failure-aclf-market
• Adenoid Cystic Carcinoma Market: https://www.delveinsight.com/report-store/adenoid-cystic-carcinom-market
• Adrenal Insufficiency Market: https://www.delveinsight.com/report-store/adrenal-crisis-market
• Age Related Vision Dysfunction Market: https://www.delveinsight.com/report-store/age-related-vision-dysfunction-market
• Allergic Rhinitis Market: https://www.delveinsight.com/report-store/allergic-rhinitis-market
• Alopecia Aerata Market: https://www.delveinsight.com/report-store/alopecia-areata-market
• Alpha Antitrypsin Market: https://www.delveinsight.com/report-store/alpha-1-antitrypsin-deficiency-a1atd-market
• Anorectal Malformation Market: https://www.delveinsight.com/report-store/anorectal-malformation-market
• Anovulation Market: https://www.delveinsight.com/report-store/anovulation-market
• Antibody Mediated Rejection Market: https://www.delveinsight.com/report-store/antibody-mediated-rejection-market
• Antibody-mediated Rejection Market: https://www.delveinsight.com/report-store/antibody-mediated-rejection-market
• Aortic Stenosis Market: https://www.delveinsight.com/report-store/aortic-stenosis-market
• Arthroscopic Shavers Market: https://www.delveinsight.com/report-store/arthroscopic-shavers-market
• Artificial Iris Market: https://www.delveinsight.com/report-store/artificial-iris-market
• Autosomal Recessive Congenital Ichthyosis Market Size: https://www.delveinsight.com/report-store/congenital-ichthyosis-market
• Bacteremia Market: https://www.delveinsight.com/report-store/bacteremia-market
• Bartonellosis Market: https://www.delveinsight.com/report-store/bartonellosis-market
• Biliary Tumor Market: https://www.delveinsight.com/report-store/biliary-tract-cancers-btcs-market
• Brain Cancer Market: https://www.delveinsight.com/report-store/brain-cancer-market
• Calcinosis Cutis Market: https://www.delveinsight.com/report-store/calcinosis-cutis-market
• Calciphylaxis Market: https://www.delveinsight.com/report-store/calciphylaxis-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Chemotherapy Induced Thrombocytopenia Market: https://www.delveinsight.com/report-store/chemotherapy-induced-thrombocytopenia-cit-market
• Cholangiocarcinoma Market: https://www.delveinsight.com/report-store/cholangiocarcinoma-cca-market-insights-epidemiology-and-market-forecast
• Chronic Inducible Urticaria Market: https://www.delveinsight.com/report-store/chronic-spontaneous-urticaria-market
• Chronic Myelogenous Leukemia Market: https://www.delveinsight.com/report-store/chronic-myelocytic-leukemia-cml-market
• Chronic Pruritus Market: https://www.delveinsight.com/report-store/chronic-pruritus-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.